News bites: Faith in markets

The idea that the private sector will better control costs than Medicare is based on a "faith-based analysis," noted health economist Uwe Reinhardt writes on The New York Times's Economix blog.

Federal prosecutors are seeking roughly $1 billion to resolve a long-running probe into Johnson & Johnson's marketing of the antipsychotic drug Risperdal, The Wall Street Journal reports (subscription required). 

Freshman Rep. Adam Kinzinger (R-Ill.) continues his assault against Democrats' Medicare "demagoguery" at The Hill.

Some people in the U.S. might have been wrongly executed because of inaccuracies in the IQ tests used to assess them, says a story in Britain's New Scientist.